DK1107737T3 - Mikropartikler til anvendelse ved nålelös injektion - Google Patents

Mikropartikler til anvendelse ved nålelös injektion

Info

Publication number
DK1107737T3
DK1107737T3 DK99943130T DK99943130T DK1107737T3 DK 1107737 T3 DK1107737 T3 DK 1107737T3 DK 99943130 T DK99943130 T DK 99943130T DK 99943130 T DK99943130 T DK 99943130T DK 1107737 T3 DK1107737 T3 DK 1107737T3
Authority
DK
Denmark
Prior art keywords
microparticles
needless injection
therapeutic agent
needless
agent
Prior art date
Application number
DK99943130T
Other languages
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1107737(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of DK1107737T3 publication Critical patent/DK1107737T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Disintegrating Or Milling (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Glanulating (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK99943130T 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion DK1107737T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles

Publications (1)

Publication Number Publication Date
DK1107737T3 true DK1107737T3 (da) 2004-08-02

Family

ID=10838317

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943130T DK1107737T3 (da) 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion

Country Status (15)

Country Link
US (3) US20020197325A1 (da)
EP (2) EP1410792B1 (da)
JP (2) JP2002524411A (da)
CN (1) CN1315854A (da)
AT (2) ATE386507T1 (da)
AU (1) AU5640799A (da)
BR (1) BR9913456A (da)
CA (1) CA2342206C (da)
DE (2) DE69938201T2 (da)
DK (1) DK1107737T3 (da)
ES (2) ES2301929T3 (da)
GB (1) GB9819272D0 (da)
IL (1) IL141323A0 (da)
MX (1) MXPA01002323A (da)
WO (1) WO2000013668A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158961A1 (en) * 1999-03-08 2001-12-05 PowderJect Research Limited Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
EP1399132A1 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Production of hard, dense particles
KR100951750B1 (ko) 2001-11-01 2010-04-09 노바르티스 아게 분무 건조 방법 및 그 조성물
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2006103671A1 (en) * 2005-03-31 2006-10-05 Rafael Armament Development Authority Ltd. Apparatus for treating particles and liquids by ultrasound
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
CA2640165A1 (en) * 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
CN101500616A (zh) 2006-08-04 2009-08-05 巴克斯特国际公司 预防和/或逆转新发作自身免疫糖尿病的基于微球的组合物
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
JP7054954B2 (ja) * 2018-01-10 2022-04-15 ジー２ジーバイオ インコーポレイテッド コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
EP0664701B1 (en) * 1992-10-16 1997-09-10 Glaxo Group Limited Taste-masking compositions of ranitidine
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
AU697456B2 (en) * 1994-06-15 1998-10-08 Dumex-Alpharma A/S Pellets
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
CA2342206C (en) 2006-12-12
DE69916856D1 (de) 2004-06-03
EP1410792A1 (en) 2004-04-21
GB9819272D0 (en) 1998-10-28
IL141323A0 (en) 2002-03-10
US20070026081A1 (en) 2007-02-01
MXPA01002323A (es) 2002-05-08
ATE386507T1 (de) 2008-03-15
CA2342206A1 (en) 2000-03-16
JP2002524411A (ja) 2002-08-06
EP1410792B1 (en) 2008-02-20
EP1107737B1 (en) 2004-04-28
EP1410792A8 (en) 2004-12-29
JP2006096755A (ja) 2006-04-13
CN1315854A (zh) 2001-10-03
US20050002870A1 (en) 2005-01-06
EP1107737A1 (en) 2001-06-20
WO2000013668A1 (en) 2000-03-16
ATE265204T1 (de) 2004-05-15
ES2223181T3 (es) 2005-02-16
US20020197325A1 (en) 2002-12-26
ES2301929T3 (es) 2008-07-01
BR9913456A (pt) 2001-07-24
AU5640799A (en) 2000-03-27
DE69938201T2 (de) 2009-02-12
DE69916856T2 (de) 2005-04-21
DE69938201D1 (de) 2008-04-03

Similar Documents

Publication Publication Date Title
DK1107737T3 (da) Mikropartikler til anvendelse ved nålelös injektion
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
HUT76258A (en) Compositions comprising dna damaging agents and p53, and methods for uses thereof
EP0757717A4 (en) PAPILLOMAVIRUS VACCINE
WO1999014346A3 (en) SENSE mRNA THERAPY
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
NO961291L (no) Prosess II
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
IL139616A0 (en) Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating, diseases caused by deficiencies thereof
ITRM960364A0 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
MD990258A (en) Method of treatment of the acute viral hepatitis B
ATE271852T1 (de) Verbesserte inhalationspräparate
FR2792318B1 (fr) Derives d'indazole, leur preparation et leur application en therapeutique
HU913267D0 (en) Process for the production of 1-(3,4-dihydro-2-oxo-1h-kinoline-6-yl)-2-(4-)2-phenyl-ethyl-(piperidine-1-yl)-ethanole and ethanone, and of medical preparations containing them as active agents
SE0100684D0 (sv) New subject-matter
GB2395903B (en) Dickkopf 5 gene, protein and antibodies: a role in the treatment and diagnosis of insulin-resistant states
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
IT1285158B1 (it) Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
PL345710A1 (en) 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
ES8505968A1 (es) Procedimiento para preparar (6-(etil-(2-hidroxipropil)-amino)-3-piridazinil)-hidrazinocarboxilato de etilo
DE69726602D1 (en) Hepatitis b inhibitoren
Hamilton ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset
RU2000112951A (ru) Способ лечения гифемы